Details for Patent: 5,616,599
✉ Email this page to a colleague
Summary for Patent: 5,616,599
Title: | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Abstract: | Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound. |
Inventor(s): | Yanagisawa; Hiroaki (Tokyo, JP), Fujimoto; Koichi (Tokyo, JP), Amemiya; Yoshiya (Tokyo, JP), Shimoji; Yasuo (Tokyo, JP), Kanazaki; Takuro (Tokyo, JP), Koike; Hiroyuki (Tokyo, JP), Sada; Toshio (Tokyo, JP) |
Assignee: | Sankyo Company, Limited (Tokyo, JP) |
Application Number: | 08/378,650 |
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
Drugs Protected by US Patent 5,616,599
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 5,616,599
International Family Members for US Patent 5,616,599
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 0503785 | ⤷ Sign Up | SPC/GB03/024 | United Kingdom | ⤷ Sign Up |
European Patent Office | 0503785 | ⤷ Sign Up | 03C0037 | France | ⤷ Sign Up |
European Patent Office | 0503785 | ⤷ Sign Up | 300133 | Netherlands | ⤷ Sign Up |
European Patent Office | 0503785 | ⤷ Sign Up | 91056 | Luxembourg | ⤷ Sign Up |
European Patent Office | 0503785 | ⤷ Sign Up | CA 2006 00012 | Denmark | ⤷ Sign Up |
European Patent Office | 0503785 | ⤷ Sign Up | 91330 | Luxembourg | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |